Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib
- 18 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 85 (5), 1003-1007
- https://doi.org/10.1007/s00280-020-04071-7
Abstract
Purpose Pexidartinib (PLX3397) is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor under clinical evaluation for potential CNS tumor treatment. This study aims to evaluate plasma pharmacokinetic parameters and estimate CNS penetrance of pexidartinib in a non-human primate (NHP) cerebrospinal fluid (CSF) reservoir model. Methods Five male rhesus macaques, each with a previously implanted subcutaneous CSF ventricular reservoir and central venous lines, were used. NHPs received a single dose of 40 mg/kg pexidartinib (human equivalent dose of 800 mg/m2), administered orally as 200 mg tablets. Serial paired samples of blood and CSF were collected at 0–8, 24, 48, and 72 h. Pexidartinib concentrations were assayed by Integrated Analytical Solutions, Inc. (Berkeley, CA, USA) using HPLC/MS/MS. Pharmacokinetic (PK) analysis was performed using noncompartmental methods. Results Samples from four NHPs were evaluable. Average (± SD) plasma PK parameters were as follows: Cmax = 16.50 (± 6.67) μg/mL; Tmax = 5.00 (± 2.58) h; AUClast = 250.25 (± 103.76) h*μg/mL; CL = 0.18 (± 0.10) L/h/kg. In CSF, pexidartinib was either quantifiable (n = 2), with Cmax values of 16.1 and 10.1 ng/mL achieved 2–4 h after plasma Tmax, or undetected at all time points (n = 2, LLOQCSF = 5 ng/mL). Conclusion Pexidartinib was well-tolerated in NHPs, with no Grade 3 or Grade 4 toxicities. The CSF penetration of pexidartinib after single-dose oral administration to NHPs was limited.Keywords
Funding Information
- National Cancer Institute (ZIA BC 011340)
This publication has 18 references indexed in Scilit:
- Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyNeuro-Oncology, 2015
- Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorThe New England Journal of Medicine, 2015
- Development of a cerebrospinal fluid lateral reservoir model in rhesus monkeys (Macaca mulatta).2015
- Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTsClinical Cancer Research, 2014
- Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibitionActa Neuropathologica, 2012
- Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) SignalingMolecular Medicine, 2012
- Quantitative Membrane Protein Expression at the Blood–Brain Barrier of Adult and Younger Cynomolgus MonkeysJournal of Pharmaceutical Sciences, 2011
- Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differencesFluids and Barriers of the CNS, 2011
- Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytesTrends in Immunology, 2002
- Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficientop/op mouse: Evidence for a role of CSF-1-dependent macrophages in formation of tumor stromaInternational Journal of Cancer, 1996